


HEALTHCARE

The Gastrointestinal Market Outlook to 2012

By Melissa Zebrowski

 [Table of Contents](#)

Melissa Zebrowski

Melissa Zebrowski is a pharmaceutical industry analyst with over seven years' of experience in healthcare and biopharma policy. During this time she has worked for four years as a consultant providing market research and analysis services, with a therapeutic focus spanning Oncology, Central Nervous System, Gastrointestinal, and Infectious Disease areas.

Copyright © 2007 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

The Gastrointestinal Market Outlook to 2012

Executive Summary	12
Patient potential of GIT therapeutic area	12
Global market analysis	13
Pipeline analysis	14
Competitive landscape	15
Chapter 1	18
Patient potential of GIT therapeutic area	
Summary	18
Introduction	19
Gastroesophageal reflux disorder	21
Overview	21
Diagnosis, treatment and management	22
Epidemiology	23
Forecast epidemiology	25
Peptic ulcer disease	26
Overview	26
Diagnosis, treatment and management	28
Epidemiology	29
Forecast epidemiology	30
Irritable bowel syndrome	32
Overview	32
Diagnosis, treatment and management	33
Epidemiology	34
Forecast epidemiology	36
Ulcerative colitis	37
Overview	37
Diagnosis, treatment and management	38
Epidemiology	39
Forecast epidemiology	40
Crohn's disease	41
Overview	41
Diagnosis, treatment and management	42
Epidemiology	43
Forecast epidemiology	45

Chapter 2 Global market analysis 48

Summary	48
Introduction	49
Market analysis by country	49
Licensing trends	50
Market analysis by drug class	51
Leading brand dynamics	54
Key events in the GIT market	56
Gastroesophageal reflux disorder and peptic ulcer disease	57
Leading brands of the GERD/PUD market	60
Proton pump inhibitor market analysis	62
Market dynamics	62
Key brands analysis	62
Histamine-2 receptor antagonist market analysis	71
Market dynamics	71
Key brands analysis	72
GERD/PUD sales forecasts to 2012	76
Irritable bowel syndrome	77
Competitive dynamics of IBS subclasses	77
Leading brands of the IBS market	80
GI sensorimotor modulators market analysis	81
Market dynamics	81
Key brands analysis	82
Antispasmodics/anticholinergics	85
Market dynamics	85
IBS sales forecasts to 2012	87
Inflammatory bowel disease: Crohn's disease and ulcerative colitis	88
Competitive dynamics of Crohn's disease and ulcerative colitis subclasses	88
Leading brands of IBD subclasses	91
Immunosuppressants market analysis	93
Market dynamics	93
Key brands analysis	94
Anti-rheumatic agents	98
Market dynamics	98
Key brands analysis	98
Intestinal anti-inflammatory agents	101
Market dynamics	101
Key brands analysis	101
IBD sales forecasts to 2012	103
Total GIT sales forecasts to 2012	104

Chapter 3 Pipeline analysis 106

Summary	106
----------------	------------

Introduction	107
Key trends in R&D	107
Increasing penetration of generics in the GERD/PUD market will continue to limit R&D investment	107
Continuing, yet uncertain focus on drug development in irritable bowel syndrome	108
Emerging therapies for the management of inflammatory bowel disease	108
New mechanism of action	108
The GIT therapeutic area pipeline	109
Leading drugs in development	110
Profiles of key pipeline products	111
Phase II compounds	111
tetomilast (OPC-6535)	111
Alicaforsen (ISIS 2302)	112
OX-17	113
S-tenatoprazole-Na	114
Phase III compounds	116
Renzapride	116
Kremezin (AST-120)	118
Cimzia (certolizumab pegol)	119
TAK-390MR (dexlansoprazole)	121
Orencia (abatacept)	122
Drugs in registration	125
Ramosetron	125
Recently marketed drugs	126
Amitiza (lubiprostone)	126
Pipeline forecasts	128
Factors affecting forecasts	128
GIT pipeline forecasts	129

Chapter 4 Competitive landscape 132

Summary	132
Introduction	133
Market share	133
AstraZeneca	136
Overview	136
Sales focus by drug class	136
Marketed product portfolio	137
R&D pipeline	138
Strategic analysis	139
Sales and promotions	139
Growth drivers	139
Growth constraints	139
Wyeth	141
Overview	141

Sales focus by drug class	141
Marketed product portfolio	142
R&D pipeline	143
Strategic analysis	144
Sales and promotions	144
Growth drivers	145
Growth constraints	145
Abbott	146
Overview	146
Sales focus by drug class	146
Marketed product portfolio	147
R&D pipeline	148
Strategic analysis	149
Sales and promotions	149
Growth drivers	150
Growth constraints	150
Johnson & Johnson	151
Overview	151
Sales focus by drug class	151
Marketed product portfolio	152
R&D pipeline	153
Strategic analysis	154
Sales and promotions	154
Growth drivers	154
Growth constraints	155
Takeda	156
Overview	156
Sales focus by drug class	156
Marketed product portfolio	157
R&D pipeline	158
Strategic analysis	159
Sales and promotions	159
Growth drivers	159
Growth constraints	160
Novartis	161
Overview	161
Sales focus by drug class	161
Marketed product portfolio	162
R&D pipeline	163
Strategic analysis	164
Sales and promotions	164
Growth drivers	165
Growth constraints	165
Astellas	166
Overview	166
Sales focus by drug class	166
Marketed product portfolio	167
R&D pipeline	168
Strategic analysis	169

	Sales and promotions	169
	Growth drivers	169
	Growth constraints	170
Eisai		171
Overview		171
Sales focus by drug class		171
Marketed product portfolio		172
R&D pipeline		172
Strategic analysis		173
	Sales and promotions	173
	Growth drivers	173
	Growth constraints	173
Altana		175
Overview		175
Sales focus by drug class		175
Marketed product portfolio		176
R&D pipeline		176
Strategic analysis		177
	Sales and promotions	177
	Growth drivers	177
	Growth constraints	177
Procter & Gamble		179
Overview		179
Sales focus by drug class		179
Marketed product portfolio		180
R&D pipeline		180
Strategic analysis		181
	Sales and promotions	181
	Growth drivers	181
	Growth constraints	182
Chapter 5	Appendix	184
IMS data		184
Licensing status		184
Index		186
Index		186

List of Figures

Figure 2.1:	Global GIT market share by geography, 2006	49
Figure 2.2:	Licensing status of global GIT sales, 2005-06 (\$bn)	50
Figure 2.3:	Competitive dynamics of the global GIT market by drug class, 2006	53
Figure 2.4:	Competitive dynamics of the leading 10 brands in the global GIT market, 2005-06	55
Figure 2.5:	Competitive dynamics of the global GERD/PUD market, 2005-06	59
Figure 2.6:	Competitive dynamics of the leading 10 brands in the global GERD/PUD market, 2005-06	61
Figure 2.7:	Competitive dynamics of the global IBS market, 2005-06	79
Figure 2.8:	Competitive dynamics of the leading 10 brands in the global IBS market, 2005-06	81
Figure 2.9:	Competitive dynamics of the global IBD market, 2005-06	90
Figure 2.10:	Competitive dynamics of the leading 10 brands in the global IBD market, 2005-06	93
Figure 3.11:	Prevailing R&D approaches	107
Figure 3.12:	The GIT pipeline by indication and stage of development, 2006	109
Figure 3.13:	Recently launched products and late-stage R&D compounds indicated for the GIT therapeutic area, 2006	110
Figure 4.14:	Competitive dynamics of the leading players in the global GIT market, 2006	135
Figure 4.15:	AstraZeneca's GIT sales, 2006 (\$m)	136
Figure 4.16:	Wyeth's GIT sales, 2006 (\$m)	141
Figure 4.17:	Abbott's GIT sales, 2006 (\$m)	146
Figure 4.18:	J&J's GIT sales, 2006 (\$m)	151
Figure 4.19:	Takeda's GIT sales, 2006 (\$m)	156
Figure 4.20:	Novartis' GIT sales, 2006 (\$m)	161
Figure 4.21:	Astellas' GIT sales, 2006 (\$m)	166
Figure 4.22:	Eisai's GIT sales, 2006 (\$m)	171
Figure 4.23:	Altana's GIT sales, 2006 (\$m)	175
Figure 4.24:	P&G's GIT sales, 2006 (\$m)	179

List of Tables

Table 1.1:	Estimated prevalence of major GIT indications in the seven major pharmaceutical markets, 2006	20
Table 1.2:	Estimated prevalence of GERD across the seven major markets, 2006	23
Table 1.3:	Forecast epidemiology of GERD across the seven major markets, 2006-12	25
Table 1.4:	Estimated prevalence of PUD in the seven major pharmaceutical markets, 2006	29
Table 1.5:	Forecast epidemiology of PUD across the seven major markets, 2006-12	31
Table 1.6:	Estimated prevalence of IBS in the seven major pharmaceutical markets, 2006	34
Table 1.7:	Forecast epidemiology of IBS across the seven major markets, 2006-12	36
Table 1.8:	Estimated prevalence of ulcerative colitis in the seven major pharmaceutical markets, 2006	39
Table 1.9:	Estimated epidemiology of UC across the seven major markets, 2006-12	40
Table 1.10:	Estimated prevalence of Crohn's disease in the seven major pharmaceutical markets, 2006	43

Table 1.11:	Forecast prevalence of Crohn’s disease across the seven major markets, 2006–12	45
Table 2.12:	Market size (\$m) and growth (%) of drug classes within the global GIT market, 2002-06	51
Table 2.13:	Market size (\$m) and growth (%) of leading brands in the global GIT market, 2005–06	54
Table 2.14:	Market size (\$m) and growth (%) of drug classes within the global GERD and PUD market, 2002-06	57
Table 2.15:	Market size (\$m) and growth (%) of leading GERD/PUD products, 2005–06	60
Table 2.16:	GERD/PUD sales forecast, 2006-12 (\$m)	76
Table 2.17:	Market size (US\$) and growth (%) of drug classes within the global IBS market, 2002-06	77
Table 2.18:	Market size (\$m) and growth (%) of leading IBS brands, 2005–06	80
Table 2.19:	IBS sales forecast, 2006-12 (\$m)	87
Table 2.20:	Market Share (\$m) and growth (%) of drug classes within the global IBD market, 2002-06	88
Table 2.21:	Market size (\$m) and growth (%) of leading IBD brands, 2005–06	91
Table 2.22:	IBD sales forecast, 2006-12 (\$m)	103
Table 2.23:	GIT therapeutic sales forecasts by drug class, 2006-12 (\$m)	104
Table 3.24:	GIT pipeline sales forecasts, 2006-12 (\$m)	129
Table 4.25:	Market share (\$m) and growth (%) of leading corporations in the global GIT market, 2005-06	133
Table 4.26:	AstraZeneca’s GIT portfolio sales, 2005-06 (\$m)	137
Table 4.27:	AstraZeneca’s R&D product pipeline, 2006	138
Table 4.28:	Promotional spend on major GIT drugs by AstraZeneca, 2005-06 (\$m)	139
Table 4.29:	Wyeth’s GIT portfolio sales, 2005-06 (\$m)	142
Table 4.30:	Wyeth’s R&D product pipeline, 2006	144
Table 4.31:	Promotional spend on major GIT drugs by Wyeth, 2005-06 (\$m)	144
Table 4.32:	Abbott’s GIT portfolio sales, 2005-06 (\$m)	147
Table 4.33:	Abbott’s R&D product pipeline, 2006	148
Table 4.34:	Promotional spend on major GIT drugs by Abbott, 2005-06 (\$m)	149
Table 4.35:	J&J’s GIT portfolio sales, 2005-06 (\$m)	153
Table 4.36:	J&J’s R&D product pipeline, 2006	153
Table 4.37:	Promotional spend on major drugs by J&J, 2005-06 (\$m)	154
Table 4.38:	Takeda’s GIT portfolio sales, 2005-06 (\$m)	157
Table 4.39:	Takeda’s R&D product pipeline, 2006	158
Table 4.40:	Promotional spend on major drugs by Takeda, 2005-06	159
Table 4.41:	Novartis’ GIT portfolio sales, 2005-06 (\$m)	162
Table 4.42:	Novartis’ R&D product pipeline, 2006	164
Table 4.43:	Promotional spend on major drugs by Novartis, 2005-06 (\$m)	164
Table 4.44:	Astellas’ GIT portfolio sales, 2005-06 (\$m)	167
Table 4.45:	Astellas’ R&D product pipeline, 2006	168
Table 4.46:	Promotional spend on major drugs by Astellas, 2005-06	169
Table 4.47:	Eisai’s GIT portfolio sales, 2005-06 (\$m)	172
Table 4.48:	Eisai’s R&D product pipeline, 2006	172
Table 4.49:	Promotional spend on major drugs by Eisai, 2005-06	173
Table 4.50:	Altana’s GIT portfolio sales, 2005-06 (\$m)	176
Table 4.51:	Promotional spend on major drugs by Altana, 2005-06	177
Table 4.52:	P&G’s GIT portfolio sales, 2005-06 (\$m)	180
Table 4.53:	P&G’s R&D product pipeline, 2006	181